The Role of the Obstetrician-Gynecologist in AIDS Prevention: The American Experience

  • Richard H. Schwarz


The obstetrician-gynecologist is uniquely positioned to have a significant role in HIV prevention, in two ways. First, as the primary and often the only health care system contact for women in the reproductive age group, the obstetrician-gynecologist sees these women in a variety of circumstances ranging from family planning, to preconceptional, to prenatal, post partum, routine annual examinations, and more. Each of these occasions provides the opportunity, most often in a conducive setting, to review the social, sexual, and other relevant history, and to offer education, counselling, and testing if appropriate. Second, and perhaps in many ways more exciting, we have the opportunity to significantly reduce the rate of vertical transmission, if we can counsel and identify pregnant women and treat them with AZT as demonstrated in the 076 study. In the first instance, it is extremely difficult to measure the impact of our efforts on the behavior of patients and specifically to assign credit for any reduction in the number of new infections. In contrast, in the case of perinatal transmission, the demonstration of positive results was so dramatic as to cause the monitors of the AIDS Clinical Trials Group 076 study to abandon the controlled trial in February of 1994 and recommend AZT use for this purpose. The perinatal transmission rate in this study, conducted primarily in the United States (and one site in France), was reduced from 25.5% to 8.3%. [1,2] Although it is not likely to continue, the results with this approach in our own institution are even more striking, with only one infected neonate in the last forty born to HIV-infected mothers who received AZT according to the protocol.


Risk Behavior Civil Liberty Post Partum American Experience Perinatal Transmission 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Connor EM, Sperling RS, Gelber R, et al. “Reduction of maternal-infant transmission of human immunodeficiency virus with zidovudine treatment.” New England Journal of Medicine 1994, 331: 1173–1180.PubMedCrossRefGoogle Scholar
  2. 2.
    Cotton P. “Trial halted after drug cuts maternal HIV transmission by two-thirds.” JAMA 1994, 271: 807.PubMedCrossRefGoogle Scholar
  3. 3.
    Chin J, Remenyi MA, Morrison F, Bulatao R. “The global epidemiology of the HIV/AIDS pandemic and its projected demographic impact in Africa.” World Health Stat Q 1992, 45: 220.PubMedGoogle Scholar
  4. 4.
    New York State Department of Health — AIDS Institute. “Clinicians guide to HIV prevention and post-test counselling,” 1995.Google Scholar
  5. 5.
    Minkoff H, Willoughby A. “Pediatric HIV disease, zidovudine in pregnancy, and unblinding heelstick surveys.” JAMA 1995, 274: 1165.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1996

Authors and Affiliations

  • Richard H. Schwarz
    • 1
  1. 1.Health Science Center at BrooklynState University of New YorkBrooklynUSA

Personalised recommendations